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OBJECTIVE—To evaluate the signiﬁcance of GAD antibodies
(GADAs) and family history for type 1 diabetes (FHT1) or type 2
diabetes (FHT2) in nondiabetic subjects.
RESEARCH DESIGN AND METHODS—GADAs were ana-
lyzed in 4,976 nondiabetic relatives of type 2 diabetic patients or
control subjects from Finland. Altogether, 289 (5.9%) were
GADA
—a total of 253 GADA
 and 2,511 GADA
 subjects
participated in repeated oral glucose tolerance tests during a
median time of 8.1 years. The risk of progression to diabetes was
assessed using Cox regression analysis.
RESULTS—Subjects within the highest quartile of GADA

(GADA

high) had more often ﬁrst-degree FHT1 (29.2 vs. 7.9%, P 
0.00001) and GADA
 type 2 diabetic (21.3 vs. 13.7%, P  0.002) or
nondiabetic (26.4 vs. 13.3%, P  0.010) relatives than GADA

subjects. During the follow-up, the GADA
 subjects developed
diabetes signiﬁcantly more often than the GADA
 subjects
(36/253 [14.2%] vs. 134/2,511 [5.3%], P  0.00001). GADA

high
conferred a 4.9-fold increased risk of diabetes (95% CI 2.8–8.5)
compared with GADA
—seroconversion to positive during the
follow-up was associated with 6.5-fold (2.8–15.2) and ﬁrst-degree
FHT1 with 2.2-fold (1.2–4.1) risk of diabetes. Only three subjects
developed type 1 diabetes, and others had a non–insulin-depen-
dent phenotype 1 year after diagnosis. GADA
 and GADA

subjects did not clinically differ at baseline, but they were leaner
and less insulin resistant after the diagnosis of diabetes.
CONCLUSIONS—GADA positivity clusters in families with type
1 diabetes or latent autoimmune diabetes in adults. GADA
positivity predicts diabetes independently of family history of
diabetes, and this risk was further increased with high GADA
concentrations. Diabetes 59:416–422, 2010
L
atent autoimmune diabetes in adults (LADA) was
introduced nearly 2 decades ago to separate a
GAD antibody (GADA)-positive subgroup of adult
patients initially diagnosed with type 2 diabetes
(1,2). Using this deﬁnition with the add-on criteria of no
exogenous insulin during the ﬁrst 6–12 months, the prev-
alence of LADA among unselected “type 2 diabetic pa-
tients” is 25% in subjects younger than 35 years and
between 4 and 13% in subjects older than 35 years at
diagnosis in populations of European origin (3–9). In
follow-up studies, a progressive defect in insulin secretion
was observed in 50–60% of LADA patients within 6–10
years (3,10), which led to the inclusion of these patients as
a slowly progressing form of type 1 diabetes in the last
World Health Organization (WHO) classiﬁcation of diabe-
tes (11). However, both the existence of LADA as a distinct
subgroup of diabetes and the criteria that should be used
to diagnose it have been challenged (e.g., (12,13). The
LADA group is heterogeneous, and most studies have been
cross-sectional, whereas prospective studies including pa-
tients at or before diagnosis and population-based studies
are few (3,4,14–16). Genetic background, especially for
type 1 diabetes, may be a confounding factor, and we have
shown that LADA was more frequent in families with both
type 1 and type 2 diabetes than in families with type 2
diabetes only (17). Moreover, some data support that type
1 and type 2 diabetes cluster in same families (17–20),
although this has been contradicted in a large U.K. study
on parents of type 1 diabetic patients (21).
In children, progression to diabetes has been associated
with high antibody levels and early development of multi-
ple autoantibodies, whereas subjects with a later appear-
ance of antibodies had a slower progression (22–25). We
have previously hypothesized that GADAs would be a
marker of a subclinical autoimmune process and showed
that GADA positivity was associated with a decrease in
maximal insulin secretory capacity in nondiabetic subjects
(26). If that is the case, GADAs should also be a predictor
of future diabetes in adults. This was not supported by two
studies on the general population (16,27), but a Swedish
study reported a sixfold increased risk for diabetes in
GADA
 subjects (15).
In a prospective follow-up study of a large cohort of
relatives of type 2 diabetic patients and population control
subjects from Finland, we have now evaluated the predic-
tive value of GADAs and family history for type 1 or type
2 diabetes in conjunction with the traditional risk factors
for diabetes.
RESEARCH DESIGN AND METHODS
The Botnia Study is a study recruiting type 2 diabetic patients and their family
members from Western Finland since 1990, as well as families with type 2
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Finland since 1994 (28,29). The study was subsequently extended to other
parts of Finland and southern Sweden. The nondiabetic subjects were invited
for follow-up examinations approximately every 3 years (29). GADA data were
available for 4,976 nondiabetic subjects over 20 years of age at the baseline
examination: 4,208 relatives diabetic patients including 92 patients with only
family history for type 1 diabetes (FHT1) and 768 control subjects without
family history of diabetes (spouses of the diabetic patients). Altogether 289
nondiabetic subjects were GADA positive (GADA
). Follow-up data were
available for 253 (87.5%) of the 289 GADA
 and 2,511 (53.6%) of the 4,687
GADA
 subjects during a median (interquartile range [IQR]) follow-up time of
9.3 (5.3) and 8.0 (5.5) years, respectively (Fig. 1). IA2 antibody (IA2ab)
measurements were available for 249 of the 253 GADA
 subjects and for 2,049
of the 2,511 GADA
 subjects who participated in the follow-up.
The GADA concentrations of the nondiabetic subjects were compared with
those of patients previously diagnosed with type 1 [193 males/200 females,
median age 38.3 (15.9) years, age at diagnosis 19.0 (19.0) years] or type 2
diabetes [1,496 males, 636 females, age 63.4 (17.7) years, age at diagnosis 55.0
(18.0) years]. A total of 191/393 (47.8%) of the type 1 diabetic patients and
260/3,231 (8.0%) of the type 2 diabetic patients were positive for GADA at a
median duration of diabetes of 16.3 (17.5) and 7.5 (11.2) years, respectively.
Information on family history of type 1 or type 2 diabetes in ﬁrst- to
third-degree relatives was obtained from the pedigrees, which were drawn
according to information received from both the subjects and their relatives
through questionnaires or clinical investigation. Frequency of GADA positivity
in the relatives was also analyzed.
Anthropometric and metabolic measurements. As explained in detail
elsewhere (28), we measured the subjects’ weight, height, waist and hip
circumference, fat-free mass (Futrex, Gaithersburg, MD), and blood pressure
(mean of two recordings). BMI was calculated as weight (kg) divided by
height (kg/m
2). The subjects participated in a 75-g oral glucose tolerance test
(OGTT) after a 12-h overnight fast. Glucose tolerance was classiﬁed according
to the WHO criteria (11). The diagnosis of type 1 or type 2 diabetes had been
made on clinical grounds by the patients’ own physician. In addition, as a
criterion for type 2 diabetes, we used treatment with diet or oral antidiabetic
agents for at least 6 months after the diagnosis and, for type 1 diabetes,
treatment with insulin from diagnosis and a serum C-peptide concentration
0.2 nmol/l at the time of baseline investigation. Blood samples were drawn
at fasting for the measurement of, e.g., serum total cholesterol, HDL
cholesterol, triglyceride, and C-peptide concentrations, and at 10, 0, 30,
60, and 120 min for the measurement of plasma glucose and serum insulin.
Insulin resistance was estimated as the homeostasis model assessment
index (HOMAIR  fasting serum insulin  fasting plasma glucose/22.5) and
-cell function as the ratio of incremental insulin to glucose responses during
the ﬁrst 30 min of the OGTT (also called the insulinogenic index). The
disposition index was used to adjust insulin secretion for the degree of insulin
resistance (insulinogenic index/HOMAIR).
A structured questionnaire was used to collect data on other diseases,
medication, and lifestyle.
Assays. GADAs and IA2abs were determined by a radio-binding assay using
35S-labeled recombinant human GAD65 or IA-2ic produced by coupled in vitro
transcription-translation as described earlier (4). The result was expressed as
relative units until the year 2000 (for GADAs) and as international units/ml
(IU/ml) after the introduction of the WHO International Standard. The GADA
results expressed as relative units or IU/ml had a linear correlation up to a
concentration of 250 IU/ml. Levels exceeding 5 relative units or 32 IU/ml were
considered positive for GADAs and levels exceeding 5 IU/ml were considered
positive for IA2abs. In the Combinatorial Autoantibody Workshop 1998, the
sensitivity and speciﬁcity of the GADA assay were 75 and 99%, respectively. In
the Diabetes Autoantibody Standardization Program Workshops, the GADA
assay showed a sensitivity of 76–88% and a speciﬁcity of 91–96% (years 2000,
2002, 2003, and 2005), and the IA2ab assay showed a sensitivity of 72% and a
speciﬁcity of 100% (year 2005).
We measured the concentration of plasma glucose with a glucose oxidase
method (Beckman Glucose Analyzer, Beckman Instruments, Fullerton, CA).
Serum insulin was ﬁrst measured by radioimmunoassay (RIA, Linco; Pharma-
cia, Uppsala, Sweden) then by an enzyme immunoassay (EIA; DAKO, Cam-
bridgeshire, U.K.) and ﬁnally with ﬂuoroimmunometric assay (FIA,
AutoDelﬁa; Perkin Elmer Finland, Turku, Finland). For statistical analysis, the
insulin concentrations obtained using the other two assays were transformed
to cohere with the insulin concentrations obtained using the enzyme immu-
noassay. The correlation coefﬁcient between RIA and EIA as well as FIA and
EIA was 0.98 (P  0.0001). Serum total cholesterol, HDL cholesterol, and
triglyceride concentrations were measured on a Cobas Mira analyzer (Hoff-
man LaRoche, Basel, Switzerland), and LDL cholesterol concentration was
calculated using the Friedewald formula.
Statistical analysis. All statistical analyses were performed using SPSS
statistical software version 13 (SPSS, Chicago, IL). Data are expressed as
frequencies, mean  SD, or median (IQR) in the case of non-normally
distributed values. The Mann-Whitney test was used to compare group means
and the 	
2 test (Pearson) was used to compare group frequencies. The insulin
data were logarithmically transformed and a linear mixed-effects model was
used to compare group differences adjusted for age, sex, and BMI while
accounting for the underlying correlation between subjects from the same
family. Cumulative risk for diabetes was analyzed with the Cox proportional
hazards model. Variables that were found to be signiﬁcant in univariate
analyses were included in the multivariate model, and GADA positivity was
used as a time-dependent variable, since some subjects became positive
during the follow-up. Two-sided P values 0.05 were considered statistically
signiﬁcant.
RESULTS
Altogether, 236 (4.7%) nondiabetic subjects were GADA

at the baseline visit and 53 converted to positive during the
follow-up (Fig. 1). A total of 3.9% (11/281) of the GADA

subjects were also IA2ab
 compared with only one of the
GADA
 subjects (P  0.0001). The GADA
 and GADA

groups had similar age [50.6 (22.0) versus 48.2 (23.3) years]
and sex distribution, with women predominating (55 vs.
54%). The majority of the subjects in both groups had
normal glucose tolerance (69.6 vs. 71.9%), and about
one-third had impaired glucose tolerance or impaired
fasting glucose (30.4 vs. 28.1%). A total of 15.7 and 15.4% of
the GADA
 and GADA
 subjects, respectively, were con-
trol subjects without family history of diabetes.
The GADA concentrations of the nondiabetic subjects
were compared with those of diabetic patients. Among all
GADA
 subjects in the Botnia Study, the type 1 diabetic
patients had the highest median antibody concentrations
[239 (1,865) IU/ml], even after a median duration of
diabetes of 17.4 (17.5) years followed by GADA
 type 2
diabetic patients [i.e., LADA, 74 (365) IU/ml; median
duration 7.5 (11.2) years] and GADA
 nondiabetic subjects
[46 (48) IU/ml] (P  0.00001, 2 df). However, the GADA
concentrations of these three groups overlapped, and
13.9% of the GADA
 nondiabetic subjects had concentra-
tions exceeding the median of the type 1 diabetic subjects.
In further analyses, the GADA
 nondiabetic subjects were
stratiﬁed into quartiles, and individuals having GADA
within the highest quartile (GADA

high; 
89 IU/ml) were
compared with individuals having lower concentrations
(GADA

low/med) or no antibodies (GADA
).
GADA positivity and type 1 diabetes clustered in fami-
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FIG. 1. Flowchart showing the number of relatives and control subjects
at baseline and during the follow-up according to GADA positivity and
progression to diabetes (DM).
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 subjects, partic-
ularly the GADA

high subjects had ﬁrst-degree relatives
with type 1 diabetes signiﬁcantly more often (29.2 vs. 7.9%,
P  0.00001) as well as GADA
 relatives (50 vs. 23%, P 
0.00001): both nondiabetic GADA
 relatives (26.4 vs.
13.3%, P  0.010) and GADA
 relatives diagnosed with
type 2 diabetes (LADA; 21.3 vs. 13.7%, P  0.002) (Fig. 2).
The subjects with low or medium GADA concentrations
did not differ from the GADA
 subjects with respect to
family history for type 1 diabetes, but the GADA

low/med
group had GADA
 relatives more often (33 vs. 23%, P 
0.002).
Overall, the clinical characteristics of the GADA
 and
GADA
 subjects did not differ much at baseline, but
the GADA
 subjects were a bit younger (Table 1). How-
ever, GADA

high subjects were younger and had a
blunted insulin response during OGTT (i.e., lower insu-
linogenic and disposition indexes) than subjects with
lower GADA concentrations or no GADAs (Table 1).
Development of diabetes. The GADA
 subjects devel-
oped diabetes signiﬁcantly more often than the GADA

subjects (36/253 [14.2%] vs. 134/2,511 [5.3%], P  0.00001),
and higher GADA concentrations were associated with a
higher risk (Fig. 3). Surprisingly, type 1 diabetes was
diagnosed in only three male subjects aged 31–44 years.
Two had been highly GADA
 4.0 and 5.2 years earlier and
the third was ICA
 and IA2ab
 at diagnosis. Altogether, 5
of the 11 (45.5%) IA2ab
 subjects developed diabetes.
Except for these three type 1 diabetic patients, all the
other 167 patients were diagnosed with type 2 diabetes,
and they were not treated with insulin during the ﬁrst year.
At the baseline visit, there was no difference between
the GADA
 and GADA
 subjects who were later to
develop diabetes (data not shown), except that the
GADA
 pre-diabetic subjects had a reduced waist circum-
ference (92.2 vs. 97.6 cm, P  0.019) and lower BMI (27.4
vs. 28.9 kg/m
2, P  0.059). We have previously shown that
both fasting plasma glucose and BMI were strong predic-
tors of diabetes (29), and this applied also to the GADA

group (data not shown).
As shown in Table 2, after the diagnosis of diabetes,
GADA
 patients were leaner than GADA
 patients [BMI
27.75  2.7 vs. 30.06  5.3 kg/m
2; P  0.023], but the
groups had had similar weight gain. GADA
 patients also
had less evidence of insulin resistance, as reﬂected by a
lower fasting insulin concentration [7.24 (7.9) vs. 13.13
(11.4) IU/ml, P  0.008] and lower HOMAIR index [2.09
(2.6) vs. 4.04 (3.9), P  0.008], despite similar fasting
plasma glucose (Table 2). GADA

high subjects developed
diabetes at a signiﬁcantly younger age than GADA

low/med
or GADA
 subjects [45.8 (13) vs. 63.1 (13.5) vs. 62 (19.4)
years, P  0.00014]. At diagnosis, the GADA
 diabetic
patients were comparable to other type 2 diabetic patients
included in the Botnia study, except for higher C-peptide
and lower fasting plasma glucose concentrations.
Subjects with family history for type 1 or type 2 diabetes
developed diabetes more often (143/2062, 6.9%, vs. 17/420,
4.0%; P  0.028) and at a younger age [59.7 (12.7) versus
71.8 (7.8) years, P  0.0001] than subjects without any
family history. There was no signiﬁcant difference be-
tween individuals with FHT1 (7.9%) and FHT2 (6.2%).
However, the majority of subjects with FHT1 also had type
2 diabetic relatives, so we could not analyze the effect of
pure type 1 diabetes family history. At diagnosis of diabe-
FIG. 2. The proportion of nondiabetic subjects having any GADA
 relatives (f), GADA
 nondiabetic relatives (z), GADA
 type 2 diabetic
relatives (LADA, ), or type 1 diabetic relatives (p) according to strength of GADA positivity. P < 0.0001, GADA
high versus GADA
 regarding
subjects having any GADA
 relatives or type 1 diabetic relatives; P  0.002, GADA
high versus GADA
 regarding subjects having GADA
 type 2
diabetic relatives; P  0.01, GADA
high versus GADA
 regarding subjects having nondiabetic GADA
 relatives.
GADA POSITIVITY PREDICTS DIABETES IN ADULTS
418 DIABETES, VOL. 59, FEBRUARY 2010 diabetes.diabetesjournals.orgtes, patients with ﬁrst-degree FHT1 were markedly younger
[43.2 (12.7) years] than individuals without any family
history for diabetes [71.8 (13.2) years] (P  0.005, FH

versus all other groups).
Thus, both GADA concentration and family history for
diabetes affected the risk of diabetes. However, high
GADAs was also associated with FHT1. Among control
subjects without family history for diabetes, low or me-
dium levels of GADA had no effect on diabetes incidence
(GADA

low/med vs. GADA
, 2.9 vs. 3.9%), but one of four
control subjects with high GADAs developed diabetes
(25%; P  0.035 vs. GADA
). However, among subjects
with family history for diabetes, the incidence of diabetes
was doubled between subjects with no GADA and
GADA

low/med, and it further doubled between GADA

low/
med and GADA

high (5.6 vs. 13.0 vs. 23.3%, P  0.0001).
Contrary to our hypothesis, in this respect, there was no
difference between individuals with family history for type
1 diabetes and individuals with family history for type 2
diabetes. Thus, high GADA concentrations implied a
clearly increased risk of diabetes in both relatives and
control subjects, while low or medium-high levels implied
an increased risk only in relatives of diabetic patients.
Having shown that age, sex, BMI, GADAs, and family
history of type 1 or type 2 diabetes affected the risk of
diabetes, we tested the relative effects of those variables
on the risk of future diabetes using Cox time-dependent
regression analyses and included GADAs as a time-
dependent variable. The traditional risk factors age, sex,
BMI, and fasting glucose at baseline were independent
determinants of risk (hazard ratio 1.03–2.42), and ﬁrst-
degree family history for type 1 diabetes conferred a
2.2-fold risk (95% CI 1.23–4.09, P  0.009). GADA

high
implied a 4.9-fold risk (2.80–8.51, P  0.0001), but
unexpectedly the highest risk (6.5-fold, 2.8–15.17, P 
0.00001) was associated with seroconversion to GADA

during the follow-up. Figure 2 shows the proportion of
subjects surviving without diabetes during the follow-up
according to GADA positivity, including age, sex, and
BMI in the model.
DISCUSSION
In this large population-based family study from Finland,
we have shown that in addition to the traditional risk
factors for type 2 diabetes, GADA positivity signiﬁcantly
increased the risk of diabetes. The incidence of diabetes
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FIG. 3. Development of diabetes according to strength of GADA
positivity: GADAs in the highest quartile (GADA
high) or three lower
quartiles of positivity (GADA
low/med) or no GADA (GADA
). The data
are adjusted for age, sex, and BMI. The y-axis shows the cumulative
proportion of subjects without diabetes; the x-axis shows the follow-up
time in years (P < 0.00001, Cox proportional hazards model).
TABLE 1
Clinical characteristics of the nondiabetic subjects at baseline according to the strength of GADA positivity
GADA
 P GADA

low/med P GADA

high
P (high vs.
negative)
n (male/female) 4,687 (2,107/2,580) 216 (101/115) 73 (33/40)
NGT/IGT (%) 72/28 79/30 67/33
Age at baseline (years) 48.2 (23.2) 0.036 53.8 (21.4) 0.014 43.9 (17.5)
FPG (mmol/l) 5.5  0.6 5.4  0.7 5.4  0.7
Plasma glucose 30 min (mU/l) 8.5  1.6 8.6  1.7 8.6  1.8
Plasma glucose 120 min (mU/l) 6.3  1.5 0.002 6.1  1.6 0.04 6.4  1.8
Fasting serum insulin (mU/l) 4.7 (4) 4.7 (3.5) 4.7 (4.5)
Serum insulin 30 min (mU/l) 35.9 (37.8) 41.7 (35.5) 0.053 31.9 (31.9) 0.04
Serum insulin 120 min (mU/l) 26.7 (33.2) 0.029 26.0 (31.0) 23.7 (16.7)
Fasting serum C-peptide (nmol/l) 0.5  0.3 0.5  0.3 0.5  0.3)
Insulinogenic index 12.4 (14.6) 13.5 (16) 0.032 11 (7.3) 0.013
HOMA 1.1 (1.0) 1.1 (0.9) 1.1 (1.2)
Disposition index 10.2 (12.7) 10.3 (13.3) 0.042 7.8 (11.1) 0.019
BMI (kg/m
2) 26.1  4.1 26.3  3.8 26.3  4.3
Systolic blood pressure (mmHg) 130.2  18.6 134.5  20.2 127.4  19.8
Diastolic blood pressure (mmHg) 79  10.4 80.4  10.7 78.6  10.4
A1C (%) 5.3  0.5 5.4  0.5 5.3  0.7
LDL cholesterol (mmol/l) 3.6  1.0 3.6  1.1 3.4  1.0
HDL cholesterol (mmol/l) 1.4  0.4 1.4  0.3 1.4  0.4
Triglycerides (mmol/l) 1.4  0.9 1.3  0.7 1.2  0.6
Data are means  SD or median (IQR). GADA
, no GADAs; GADA

low/med, GADAs within the three lower quartiles of positivity; GADA

high,
GADAs within the highest quartile. In the statistical analyses, a linear mixed-effects model was used to compare group differences adjusted
for age, sex, and BMI while accounting for the underlying correlation between subjects from the same family when appropriate.
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quartile of positivity (23.3%; HR 4.9, 95% CI 2.80–8.51),
intermediate in individuals having GADAs within the three
lower quartiles (13.0%), and lowest in GADA
 subjects
(5.6%). The younger age of the GADA

high group and the
shorter follow-up of the GADA
 subjects reﬂects their
increased rate of progression to diabetes, since the fol-
low-up was terminated at diagnosis of diabetes. Although
the increased risk was clearly associated with strength of
GADA reactivity, we could not distinguish a GADA cutoff,
under which diabetes would be less likely, and we ob-
served no bimodality in the GADA distribution, as has
been suggested (9). Also, seroconversion from GADA
 to
GADA
 during the follow-up conferred an increased risk
of diabetes, but IA2abs were too rare in this population to
have a high impact. GADA concentrations have been
associated with lower C-peptide concentration in cross-
sectional studies of LADA (4,30,31) as well as development
of complete -cell failure in adults with newly diagnosed
diabetes of any type (32), although data from the U.K.
Prospective Diabetes Study did not support an association
between GADA level and need of insulin (33). Phenotypi-
cally, only three of our patients who developed diabetes
had type 1 diabetes, whereas all other GADA
 patients had
type 2 diabetes. We could not see a decreased insulin
response to glucose, but the GADA
 diabetic patients
were less insulin resistant than the GADA
 patients, which
indirectly supports the hypothesis that GADAs might be
associated with a defect in insulin secretion. We have
previously shown in nondiabetic subjects with thyroiditis
that GADA
 subjects had a decreased maximal insulin
secretory capacity, as estimated with an intravenous glu-
cose-arginine test compared with GADA
 subjects (26).
Apparently, the insulin secretory defect associated with
GADAs is mild and can only be seen with a test that
stresses the -cells maximally.
GADA positivity and type 1 diabetes clustered in fami-
lies. In concert with the high prevalence of type 1 diabetes
in Finland (34), FHT1 was found in 8% of GADA
 and
GADA

low/med subjects, whereas almost one-third (29%) of
the GADA

high group had type 1 diabetic relatives. More-
over, 50% in the GADA

high and 30% of the GADA

low/med
groups had GADA
 relatives. It would be important to
study how much the known type 1 diabetes susceptibility
genes, such as HLA and PTPN22, explain of this clustering.
With this background, the high frequency of GADAs (4.7%)
among the nondiabetic relatives and even control subjects
without any family history for diabetes was not that
surprising. In a 6-year follow-up study of this population,
family history for type 2 diabetes together with BMI 
30
kg/m
2 and fasting plasma glucose 
5.5 mmol/l conferred a
3.7-fold risk of diabetes (29). We now hypothesized that
FHT1 would increase the risk of type 2 diabetes (or LADA)
through an effect on insulin secretory capacity. We were
reassured to ﬁnd that in conjunction with the other risk
factors, FHT1 doubled the risk of diabetes (HR 2.2, CI
1.23–4.01). However, even when FHT1 was in the model,
high GADAs implied an even stronger risk (HR 4.9, CI
2.8–8.5). Further, there seemed to be a difference in
incidence rates between the population control subjects
without any family history for diabetes, in whom high
GADAs only affected diabetes risk, and subjects with
family history for type 1 or type 2 diabetes, whose diabetes
risk was doubled also with low or medium-high GADAs.
Mild autoimmunity might not be sufﬁcient to cause diabe-
tes in the absence of other factors decreasing insulin
secretion or increasing insulin resistance. One such factor
could be having inherited the risk allele of the gene with
TABLE 2
Clinical characteristics of the GADA
 and GADA
 subjects at follow-up according to progression to diabetes (DM
)
GADA
 GADA

P* DM
 P DM
 DM
 P DM

n 2,377 134 216 36
Age (years) 54.6 (20.6) 0.0001 61.9 (19.4) 56.9 (20.9) 60.1 (19)
Follow-up time (years)† 8.0 (5.6) 7.7 (5.4) 9.6 (5.4) 0.001 6.3 (4.9) 0.039
A1C (%) 5.5  0.5 0.0001 6.3  0.6 5.7  0.4 0.0001 6.7  1.1 0.004
FPG (mmol/l) 5.3  0.6 0.0001 6.9  1.0 5.3  0.6 0.0001 6.9  0.9
Plasma glucose 30 min (mmol/l) 8.5  1.8 0.0001 11.5  2.2 8.4  1.7 0.0001 11.5  1.4
Plasma glucose 120 min (mmol/l) 5.9  1.7 0.0001 11.3  2.9 5.8  1.7 0.0001 10.5  2.8
Fasting insulin (mU/l) 7.3 (6.5) 0.0001 13.1 (11.4) 7.0 (7.1) 7.2 (7.9) 0.008
Serum insulin 30 min (mU/l) 53.5 (43.5) 0.0003 50.5 (46.6) 53.4 (38.0) 0.006 36.8 (37.1)
Serum insulin 120 min (mU/l) 30.9 (37.2) 0.0001 74.6 (91.9) 29.3 (33.8) 0.009 61.2 (74.7)
Fasting serum C-peptide (nmol/l) 0.5  0.3 0.0001 0.9  0.5 0.5  0.3 0.073 0.7  0.4
Insulinogenic index 14.6 (16.2) 0.0001 8.1 (10.9) 15.6 (13.2) 0.0001 6.4 (7.3)
HOMA 1.7 (1.6) 0.0001 4.0 (3.9) 1.7 (1.7) 0.036 2.1 (2.6) 0.005
Disposition index 8.8 (11.2) 0.0001 2.3 (1.9) 8.8 (10.2) 0.0001 2.9 (2.5)
Waist (cm) 91.8  12.5 0.0001 102.9  12.6 91.1  11.5 0.026 98.0  9.6
BMI (kg/m) 26.7  4.2 0.0001 30.1  5.3 26.6  4.3 27.8  2.7 0.023
Fat % 28.3  7.3 0.0001 30.2  6.4 28.8  9.3 30.0  6.2
Systolic blood pressure (mmHg) 133.5  19.6 0.0001 145.3  22 135.0  19.2 0.055 146.6  27.4
Diastolic blood pressure (mmHg) 81.4  9.9 0.0001 85.7  10.2 82.0  9.3 83.6  9.7
HDL cholesterol (mmol/l) 1.3  0.4 1.1  0.3 1.4  0.4 1.3  0.4
Triglycerides (mmol/l) 1.4  0.8 1.8  1.0 1.4  0.8 1.8  0.9
LDL cholesterol (mmol/l) 3.4  1.0 3.5  1.1 3.2  0.8 3.4  1.0
Data are means  SD or median (IQR). In the statistical analyses, a linear mixed-effects model was used to compare group differences
adjusted for age, sex, and BMI while accounting for the underlying correlation between subjects from the same family. BMI was adjusted for
age and sex. OGTT data were available for 60% of the GADA
 subjects and 87% of the GADA
 subjects who developed diabetes. *Difference
between GADA
 DM
 and GADA
 DM
. †Time until diagnosis of diabetes or until last visit.
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has been shown to decrease insulin secretion and which
was as common in LADA as in type 2 diabetes (35,36).
Although the low number of GADA
 population control
subjects precludes any ﬁrm conclusions on the difference
in risk, it could explain the difference between our study
and the two previous studies looking at the predictive
value of GADAs for diabetes in the general population,
where no increased risk was found during a comparable
8-year follow-up (16,27). Another difference between the
studies was the number of GADA
 subjects, which was
only 18 in the Italian Cremona Health Study (16) and 23 in
the Swedish Va ¨sterbotten County Health Project. How-
ever, in another part of the Va ¨sterbotten Study, 7 of 25
(28%) initially GADA
 subjects were reported to have
developed diabetes after a mean time of 9.2  2.9 years
compared with 86 of 2,209 (3.9%) of GADA
 subjects (P 
0.0001). Only one of the seven was diagnosed with type 1
diabetes (15).
In conclusion, GADA positivity clustered in families
with type 1 diabetes or LADA. GADA positivity predicted
diabetes independently of family history of diabetes, and
this risk increased with high GADA concentrations.
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